Targeting mutant RAS in patient-derived colorectal cancer organoids by combinatorial drug screening

Abstract excerpt

Colorectal cancer (CRC) organoids can be derived from almost all CRC patients and therefore capture the genetic diversity of this disease. We assembled a panel of CRC organoids carrying either wild-type or mutant RAS, as well as normal organoids and tumor organoids with a CRISPR-introduced oncogenic KRAS mutation. Using this panel, we evaluated RAS pathway inhibitors and drug combinations that are currently in...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Cells and Metastasis
• Share to Colorectal Cancer Treatments and Studies
• Share to PI3K/AKT/mTOR signaling in cancer